drug_type
RELEVANT_DRUG
intervention_type
Cell therapy
drug_description
Off-the-shelf allogeneic engineered natural killer (NK) cell therapy designed to augment antibody-directed killing; combined with tafasitamab to eliminate CD19+ B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Natural Killer Cells
drug_category
OTHER ENGINEERED IMMUNE CELL
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic engineered NK cells equipped with an enhanced Fc receptor (PluReceptor) to increase binding to therapeutic IgG1 antibodies and amplify antibody-dependent cellular cytotoxicity. In combination with tafasitamab (anti-CD19), the NK cells recognize antibody-opsonized CD19+ B cells and kill them via perforin/granzyme-mediated cytotoxicity and innate pathways, leading to depletion of pathogenic B cells.
drug_name
AD‑PluReceptor‑NK cells
nct_id_drug_ref
NCT06434363